arrow_back Back to App

Faster Access to Foreign-Approved Drugs and Medical Devices

New rules aim to streamline access to drugs, biological products, and medical devices already approved for sale in other countries. This means these products could reach the U.S. market faster if they meet specific safety and effectiveness criteria, potentially improving access to vital treatments for citizens.
Key points
Allows faster U.S. market approval for drugs and medical devices already legally sold in selected countries (e.g., United Kingdom).
Requires these products to meet safety and effectiveness criteria and address unmet medical needs in the U.S.
The FDA has 30 days to decide on approval, significantly speeding up the process compared to standard procedures.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_724
Sponsor: Rep. Roy, Chip [R-TX-21]
Process start date: 2021-02-02
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_724.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-02-02.

What are the main provisions?

Key points include:

  • Allows faster U.S. market approval for drugs and medical devices already legally sold in selected countries (e.g., United Kingdom).
  • Requires these products to meet safety and effectiveness criteria and address unmet medical needs in the U.S.
  • The FDA has 30 days to decide on approval, significantly speeding up the process compared to standard procedures.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Roy, Chip [R-TX-21].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health